https://www.nasdaq.com/press-release/report-of-placebo-controlled-clinical-trial-evaluating-multistemr-cell-therapy-for
https://www.nasdaq.com/press-release/athersys-reports-third-quarter-2021-results-and-provides-corporate-update-2021-11-15
https://www.nasdaq.com/press-release/athersys-reports-updates-on-timing-for-japan-ards-and-stroke-programs-from-healios-k
https://www.nasdaq.com/press-release/athersys-to-host-third-quarter-financial-results-call-2021-10-18
https://www.nasdaq.com/press-release/athersys-to-present-at-2021-cell-gene-meeting-on-the-mesa-hybrid-conference-2021-09
https://www.nasdaq.com/press-release/athersys-partner-healios-k.k.-completes-enrollment-in-the-treasure-study-of-multistem
https://www.nasdaq.com/press-release/athersys-reports-second-quarter-2021-results-2021-08-09
https://www.nasdaq.com/press-release/athersys-partner-healios-k.k.-announces-positive-topline-results-of-multistem-for
https://www.nasdaq.com/press-release/athersys-and-healios-k.k.-announce-advancement-of-their-multistem-commercial
https://www.nasdaq.com/press-release/athersys-to-host-second-quarter-financial-results-call-2021-07-13
https://www.nasdaq.com/press-release/new-publication-provides-further-clarity-of-multistems-mechanism-of-action-on
https://www.nasdaq.com/press-release/athersys-reports-first-quarter-2021-results-2021-05-06
https://www.nasdaq.com/press-release/athersys-to-present-at-the-bank-of-america-virtual-healthcare-conference-on-may-12
https://www.nasdaq.com/press-release/athersys-to-host-first-quarter-financial-results-call-2021-04-13
https://www.nasdaq.com/press-release/athersys-to-present-at-the-needham-virtual-healthcare-conference-on-april-14-2021-04
https://www.nasdaq.com/press-release/athersys-reports-that-healios-has-completed-enrollment-in-the-one-bridge-study-of
https://www.nasdaq.com/press-release/athersys-announces-financial-results-for-fourth-quarter-and-full-year-2020-2021-03-25
https://www.nasdaq.com/press-release/athersys-to-host-year-end-2020-financial-results-call-2021-03-02
https://www.nasdaq.com/press-release/athersys-announces-cooperation-agreement-with-healios-k.k.-2021-02-16
https://www.nasdaq.com/press-release/athersys-announces-ceo-transition-2021-02-16
https://www.nasdaq.com/press-release/athersys-to-host-a-virtual-investor-day-2021-01-28
https://www.nasdaq.com/press-release/uthealth-in-houston-and-athersys-announce-commencement-of-patient-enrollment-in-a
https://www.nasdaq.com/press-release/athersys-announces-three-appointments-to-board-of-directors-2020-11-16
https://www.nasdaq.com/press-release/athersys-reports-third-quarter-2020-results-and-provides-corporate-update-2020-11-09
https://www.nasdaq.com/press-release/athersys-to-host-third-quarter-financial-results-call-2020-10-08
https://www.nasdaq.com/press-release/fda-grants-rmat-designation-to-multistem-cell-therapy-for-the-treatment-of-acute
https://www.nasdaq.com/press-release/athersys-reports-second-quarter-2020-results-2020-08-10
https://www.nasdaq.com/press-release/athersys-to-host-second-quarter-financial-results-call-2020-07-20
https://www.nasdaq.com/press-release/athersys-announces-upcoming-presentations-at-the-international-society-of-cell-and
https://www.nasdaq.com/press-release/athersys-reports-first-quarter-2020-results-2020-05-07
https://www.nasdaq.com/press-release/athersys-announces-commencement-of-patient-enrollment-in-the-macovia-study-a-pivotal
https://www.nasdaq.com/press-release/athersys-and-university-hospitals-cleveland-medical-center-announce-activation-of-the
https://www.nasdaq.com/press-release/athersys-to-present-at-the-bank-of-america-merrill-lynch-virtual-healthcare
https://www.nasdaq.com/press-release/athersys-to-host-first-quarter-financial-results-call-2020-04-21
https://www.nasdaq.com/press-release/athersys-announces-closing-of-public-offering-of-common-stock-2020-04-20
https://www.nasdaq.com/press-release/athersys-announces-pricing-of-public-offering-of-common-stock-2020-04-15
https://www.nasdaq.com/press-release/athersys-announces-proposed-public-offering-of-common-stock-2020-04-15
https://www.nasdaq.com/press-release/fda-authorizes-initiation-of-a-phase-2-trial-evaluating-multistemr-cell-therapy-in
https://www.nasdaq.com/press-release/fda-authorizes-athersys-to-initiate-a-pivotal-clinical-trial-evaluating-multistemr
https://www.nasdaq.com/press-release/healios-k.k.-increases-investment-in-athersys-by-fully-exercising-warrant-to-acquire
https://www.nasdaq.com/press-release/athersys-names-maia-hansen-senior-vice-president-operations-and-supply-chain-2020-03
https://www.nasdaq.com/press-release/athersys-announces-financial-results-for-fourth-quarter-and-full-year-2019-2020-03-16
https://www.nasdaq.com/press-release/athersys-to-host-year-end-2019-financial-results-call-2020-02-10
https://www.nasdaq.com/press-release/athersys-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-2020-02-03
https://www.nasdaq.com/press-release/athersys-names-ivor-macleod-chief-financial-officer-2020-01-15
https://www.nasdaq.com/press-release/athersys-provides-update-on-one-year-ards-study-data-2020-01-14
https://www.nasdaq.com/press-release/healios-receives-notification-of-orphan-designation-for-acute-respiratory-distress
https://www.nasdaq.com/press-release/athersys-reports-third-quarter-2019-results-2019-11-06
